By Marie Rosenthal, MS
Nearly eight out of 10 cisgender women preferred long-acting injectable cabotegravir to daily oral pre-exposure prophylaxis (PrEP), according to the results of a study conducted in seven African countries that will be presented at IAS 2023, the 12th IAS Conference on HIV Science.
The study was an open-label extension of HPTN 084, a landmark clinical trial that demonstrated that long-acting injectable cabotegravir was superior to daily oral PrEP with emtricitabine and